Aaron Cowen’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,010
Closed -$229K – 96
2026
Q2
$229K Buy
+1,010
New +$180K ﹤0.01% 95
2026
Q1
– Sell
-1,010
Closed -$201K – 93
2025
Q4
$201K Buy
+1,010
New +$183K ﹤0.01% 93
2024
Q3
– Sell
-1,010
Closed -$209K – 101
2024
Q2
$209K Hold
1,010
– – 0.01% 97
2024
Q1
$274K Hold
1,010
– – 0.01% 101
2023
Q4
$239K Buy
+1,010
New +$199K 0.01% 87
2023
Q3
– Sell
-1,010
Closed -$212K – 92
2023
Q2
$212K Hold
1,010
– – 0.01% 98
2023
Q1
$204K Hold
1,010
– – 0.01% 93
2022
Q4
$220K Buy
+1,010
New +$221K 0.01% 86

Other funds holding CRL

Aaron Cowen's CRL Position: Q3 2026 in Review

Aaron Cowen sold out of Charles River Laboratories (CRL) in Q3 2026, closing a stake of 1,010 shares — an estimated $229K sold.

Aaron Cowen first reported a position in CRL in Q4 2022 and held it in 8 quarters. The position peaked at $274K in Q1 2024. 642 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Aaron Cowen reported no remaining Charles River Laboratories position as of Q3 2026 after selling out during the quarter.
  • Aaron Cowen sold 1,010 Charles River Laboratories shares in Q3 2026, an estimated $229K.
  • Aaron Cowen first reported a position in Charles River Laboratories in Q4 2022 and held it in 8 quarters.
  • Aaron Cowen's Charles River Laboratories position peaked at $274K in Q1 2024.
  • 642 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Suvretta Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.